Roche Grants License to Response Biomedical

By HospiMedica staff writers
Posted on 08 Aug 2005

A nonexclusive license to commercialize a key cardiac marker for an array of conditions has been granted by Roche Diagnostics (Basel, Switzerland) to Response Biomedical (Vancouver, Canada).

Specifically, Response Biomedical received a nonexclusive license under patent rights to commercialize NT-proBNP (N-terminal prohormone brain natriuretic peptide). As part of the agreement, Response Biomedical also received an option to commercialize troponin T, a cardiac marker for heart attack, for use with its RAMP system for the point-of-care (POC) market segment.

The availability of test results within minutes is vital for the assessment of patients with suspected cardiac problems. The RAMP system of Response Biomedical provides a quantitative measurement of cardiac markers in whole blood to diagnose a heart attack and provide test results in less than 15 minutes.

"This relationship with Roche Diagnostics enables Response Biomedical to significantly enhance our RAMP cardiac portfolio of FDA-cleared troponin T, CK-MB, and myoglobin tests while expanding our international marketing and distribution network over the coming months,” observed Bill Radvak, president and CEO of Response Biomedical.

Related Links:
Roche Diagnostics
Response Biomedical